News Center

First US Patient Dosed With Investigational Stem Cell Therapy IMS001 for MS

The first US patient has been dosed with an investigational stem cell therapy called IMS001, for multiple sclerosis (MS), developed by ImStem Biotechnology.

11/23

2021

06

2022.07

ImStem Files Opening Brief of Appeal to The U.S. Court of Appeals for The Federal Circuit Concerning Stem Cell Patents

05

2022.06

Watch ImStem’s scientists introduce its innovative stem cell technology on Bloomberg

31

2022.05

Bloomberg to Air ImStem’s First-ever Stem Cell Technology on June 4th

18

2021.11

ImStem Announces First US Multiple Sclerosis Patient Has Been Dosed with its IMS001

ImStem Biotechnology today announces the dosing of the first US multiple sclerosis patient with its lead investigational drug candidate IMS001 at the Shepherd Center in Atlanta, GA.